Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia

Blood

Volumn 108, Issue 10, 2006, Pages 3302-3304

  Jeha, Sima ^a   Behm, Frederick ^a   Pei, Deqing ^a   Sandlund, John T ^a   Ribeiro, Raul C ^a   Razzouk, Bassem I ^a   Rubnitz, Jeffrey E ^a   Hijiya, Nobuko ^a   Howard, Scott C ^a   Cheng, Cheng ^a   Pui, Ching Hon ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CONTROLLED STUDY; HUMAN; INFANT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PLOIDY; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 33751192892     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-04-016709     Document Type: Article

References (14)

1. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103:4396-4407.
2. Thomas DA, Cortes J, Faderl S, et al. Outcome with the hyper-CVAD and rituximab regimen in Burkitt's (BL) and Burkitt's-like (BLL) leukemia/lymphoma (abstract). Blood. 2004;104:901a.
3. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14:520-535.
4. Thomas DA, Cortes J, Giles F, et al. The modified hyper-CVAD regimen in newly diagnosed adult acute lymphoblastic leukemia (ALL) (abstract). Blood. 2001;98:590a.
5. Thomas DA, Cortes J, Giles F, et al. Update of the modified hyper-CVAD regimen in newly diagnosed adult acute lymphocytic leukemia (ALL) (abstract). Blood. 2003;102:880a.
6. Pui CH, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92:411-415.
7. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004;104:2690-2696.
8. Kishi S, Griener J, Cheng C, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol. 2003;21:3084-3091.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
10. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trails requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977;35:1-39.
11. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
12. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154.
13. Borowitz MJ, Shuster J, Carroll AJ, et al. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Study. Blood. 1997;89:3960-3966.
14. Pui CH, Sandlund JT, Pei D, et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA. 2003; 290:2061-2063.